AIM
===

The overall aim of this project was to develop an evidence-based clinical practice guideline for evaluation and management of CKD. The guideline consists of recommendation statements, rationales, and a summary of systematically generated evidence on relevant pre-defined clinical topics. To a large extent the guideline builds on the output of the KDIGO Controversies Conference in 2009,^[@bib30]^ which generated epidemiological data to support a revision of the classification and staging system. The vision for this KDIGO guideline is that it would endorse the current CKD definition as an imperfect convention for describing a state of function, revise classification based on risk, revise risk states, and revise and update action plans in view of the revised classifications. Additional systematic evidence review focused on specific topics.

OVERVIEW PROCESS
================

The guideline development process included the following steps:

Appointing Work Group members and the ERTDiscussing process, methods, and resultsDeveloping and refining topicsIdentifying populations, interventions or predictors, and outcomes of interestSelecting topics for systematic evidence reviewStandardizing quality assessment methodologyDeveloping and implementing literature-search strategiesScreening abstracts and retrieving full text articles on the basis of predefined eligibility criteriaCreating data extraction formsExtracting data and performing critical appraisal of the literatureGrading the methodology and outcomes in individual studiesTabulating data from individual studies into summary tablesGrading the strength of recommendations on the basis of the quality of evidence and other considerationsFinalizing guideline recommendations and supporting rationalesSending the guideline draft for peer review to the KDIGO Board of Directors in January 2012 and for public review in May 2012Publishing the final version of the guideline

Collaboration Among Participants
--------------------------------

The KDIGO Co-Chairs appointed the Work Group Co-Chairs, who then assembled the Work Group of domain experts, including individuals with expertise in internal medicine, adult and pediatric nephrology, diabetology/endocrinology, clinical chemistry, and epidemiology. The Tufts Center for Kidney Disease Guideline Development and Implementation at Tufts Medical Center in Boston, Massachusetts, USA, was contracted to conduct systematic evidence review and provide expertise in guideline development methodology. The ERT consisted of physician--methodologists with expertise in nephrology, a project coordinator, a research assistant, and a medical writer--editor. The ERT instructed and advised Work Group members in all steps of literature review, critical literature appraisal, and guideline development. The Work Group and the ERT collaborated closely throughout the project.

The Work Group and its Chairs, KDIGO Co-chairs, ERT, and KDIGO support staff met for three 2-day meetings for training in the guideline development process, topic discussion, and consensus development.

Throughout the project, the ERT offered suggestions for guideline development and led discussions on systematic review, literature searches, data extraction, assessment of quality and applicability of articles, evidence synthesis, grading of evidence and guideline recommendations, and consensus development. The Work Group took the primary role of writing the recommendation statements and rationales and retained final responsibility for their content.

Defining Scope and Topics
-------------------------

This KDIGO CKD guideline was set out to update the *KDOQI Clinical Practice Guidelines for CKD: Evaluation, Classification, and Stratification*^[@bib1]^ in 2002, which spans many topics related to the diagnosis, classification, stratification, and management of CKD.^[@bib1]^

The Work Group Co-Chairs prepared the first draft of the scope of work document as a series of open-ended questions to be considered by Work Group members. At their first 2-day meeting, members added further questions until the initial working document included all topics of interest to the Work Group. The inclusive, combined set of questions formed the basis for the deliberation and discussion that followed. The Work Group strove to ensure that all topics deemed clinically relevant and worthy of review were identified and addressed.

Updating the topics of definitions and classification was based on the output from the KDIGO Controversies Conference and the CKD Prognosis Consortium.^[@bib4],\ [@bib30]^

Additional topics that relate to explicit selection of diagnostic tests or interventions were chosen to undergo systematic review of the best available evidence. Systematic evidence review entails *a priori* question formulation, specification of important outcomes for the review, systematic searches, data extraction, tabulation, analysis, and synthesis of evidence and is described in detail for each of the specific questions. The process followed for each evidence review topic (a total of four non-treatment topics and four treatment topics) is detailed below.

The eight topics for which the ERT conducted searches and evidence review are shown in [Table 37](#tbl37){ref-type="table"}. For the systematic review topics, the Work Group and ERT further developed and refined each topic and specified screening criteria, literature search strategies, and data extraction forms.

Many other topics were not suitable to be addressed by in-depth evidence review. When the anticipated outcome of an extensive literature search was unlikely to yield evidence that directly informs practice choices, the approach chosen was that of a narrative review.

APPROACH TO EVIDENCE REVIEW TOPICS
==================================

Formulating Questions of Interest
---------------------------------

Questions of interest were formulated according to the PICODD (Population, Intervention or Predictor, Comparator, Outcome, study Design, and Duration of follow-up) criteria. Details of the PICODD criteria are presented in [Table 37](#tbl37){ref-type="table"}.

Literature Searches and Article Selection for Evidence Review Topics
--------------------------------------------------------------------

Search strategies were developed by the ERT, with input from the Work Group, for each topic of interest (whether treatment or non-treatment topics). The ERT performed literature searches and conducted abstract and article screening. The ERT also coordinated the methodological and analytic processes, data extraction, and summarizing of the evidence. Before initiating our own *de novo* systematic review, we searched for existing systematic reviews that could be used. The searches and search terms are provided in Supplemental Table 1 and the search dates and yields for all topics are presented in [Table 38](#tbl38){ref-type="table"}.

Selection of Outcomes of Interest
---------------------------------

The Work Group selected outcomes of interest on the basis of their importance for informing clinical decision making. Importance of mortality and ESRD was considered to be critical; the importance of progression of CKD and categorical or continuous measures of kidney function was considered to be high; and the importance of QOL, BP, gout attacks, and proteinuria was considered to be moderate.

Data Extraction
---------------

Text articles were extracted by the ERT onto forms customized to capture data on design, methodology, baseline characteristics, interventions or predictors, comparators, outcomes, results, and limitations of individual studies. Study methodology and risk of bias were also systematically graded for each outcome and recorded.

Summary Tables
--------------

Pertinent information for systematic review topics was tabulated in summary tables. Summary tables list outcomes of interest as well as relevant population characteristics, descriptions of interventions and comparators, results, and quality grades for each outcome. Categorical and continuous outcomes were summarized separately. Work Group members reviewed all summary table data and quality grades.

Evidence Profiles
-----------------

Evidence profiles are usually constructed as a means to assess the quality and record quality grades and descriptions of effect for each outcome across studies, as well as the quality grades and description of net benefits or harms of the intervention or comparator across studies. These profiles aim to make the evidence synthesis process transparent. However, since no treatment or non-treatment topic had more than one study in a summary table for which the quality was graded, no evidence profiles were generated, and the information in the summary table shows the highest level of synthesis.

Grading of Quality of Evidence for Outcomes of Individual Studies
-----------------------------------------------------------------

### Methodological quality

Methodological quality (internal validity) refers to the design, conduct, and reporting of outcomes of a clinical study. A previously devised three-level classification system for quality assessment was used to grade the overall study quality and quality of all relevant outcomes in the study ([Table 39](#tbl39){ref-type="table"}). Variations of this system have been used in most KDOQI and all KDIGO guidelines and have been recommended for the US Agency for Healthcare Research and Quality Evidence-based Practice Center program.^[@bib722]^

Each study was given an overall quality grade on the basis of its design, methodology (randomization, allocation, blinding, definition of outcomes, appropriate use of statistical methods, etc.), conduct (drop-out percentage, outcome assessment methodologies, etc.), and reporting (internal consistency, clarity, thoroughness, and precision, etc.). Each reported outcome was then evaluated and given an individual grade depending on the quality of reporting and methodological issues specific to that outcome. However, the quality grade of an individual outcome could not exceed the quality grade for the overall study.

Grading the Quality of Evidence and the Strength of Guideline Recommendations
-----------------------------------------------------------------------------

A structured approach, based on the GRADE approach,^[@bib723],\ [@bib724],\ [@bib725]^ was used to grade the quality of the overall evidence and the strength of recommendations for each topic. This grading scheme-with two levels for the strength of a recommendation together with four levels of grading for the quality of the evidence, as well as the option of an ungraded statement for general guidance-was adopted by the KDIGO Board in December 2008.

The strength of a recommendation indicates the extent to which one can be confident that adherence to the recommendation will do more good than harm. The quality of a body of evidence refers to the extent to which our confidence in an estimate of effect is sufficient to support a particular recommendation.^[@bib724]^ The process of transparently grading evidence and recommendations for treatment topics is described below in further detail. However, the approach had to be adapted for the main topics of the KDIGO CKD guideline because they were not treatment-related topics.

Grading the Quality of Evidence for Each Outcome Across Studies
---------------------------------------------------------------

Following the GRADE approach, the quality of a body of evidence pertaining to a particular outcome of interest was initially categorized on the basis of study design ([Table 40](#tbl40){ref-type="table"}). For questions of interventions, the initial quality grade was high if the body of evidence consisted of RCTs, low if it consisted of observational studies, and very low if it consisted of studies of other designs. For questions of interventions, the Work Group decided to use only RCTs. The grade for the quality of evidence for each intervention--outcome pair was then lowered if there were serious limitations to the methodological quality of the aggregate of studies, if there was thought to be a high likelihood of bias, if there were important inconsistencies in the results across studies, if there was uncertainty about the directness of evidence (including limited applicability of the findings to the population of interest), if the data were sparse (for example if there was only one study or if the results include just a few events or observations and were uninformative) or imprecise (for example the CI spans a range greater than 1 or confidence limits are \<0.5 to \>2.0). The final grade for the quality of the evidence for an intervention--outcome pair was then assigned as high, moderate, low, or very low ([Table 40](#tbl40){ref-type="table"}).

Grading the Overall Quality of Evidence
---------------------------------------

The quality of the overall body of evidence was then determined on the basis of the quality grades for all outcomes of interest, taking into account explicit judgments about the relative importance of each outcome. The resulting four final categories for the quality of overall evidence were A, B, C, and D ([Table 41](#tbl41){ref-type="table"}).

Assessment of the Net Health Benefit Across All Important Clinical Outcomes
---------------------------------------------------------------------------

The net health benefit was determined on the basis of the anticipated balance of benefits and harms across all clinically important outcomes ([Table 42](#tbl42){ref-type="table"}). The assessment of net benefit also involved the judgment of the Work Group and the ERT.

Grading the Strength of the Recommendations
-------------------------------------------

The strength of a recommendation is graded as level 1 or level 2. [Table 43](#tbl43){ref-type="table"} shows the KDIGO nomenclature for grading the strength of a recommendation and the implications of each level for patients, clinicians, and policy makers. Recommendations can be for or against doing something. [Table 44](#tbl44){ref-type="table"} shows that the strength of a recommendation is determined not only by the quality of the evidence, but also by other, often complex judgments regarding the size of the net medical benefit, values and preferences, and costs. Formal decision analyses including cost analysis were not conducted.

Ungraded Statements
-------------------

This category was designed to allow the Work Group to issue general advice. Typically an ungraded statement meets the following criteria: it provides guidance that is based on common sense, it provides reminders of the obvious, and it is not sufficiently specific to allow for application of evidence to the issue and therefore it is not based on systematic evidence review. The GRADE system is best suited to evaluate evidence on comparative effectiveness. Some of our most important guideline topics involve diagnosis and staging within CKD, about which the Work Group chose to provide ungraded statements. These statements are indirectly supported by evidence on risk relationships and are the consensus of the Work Group. Thus, we believe that ungraded statements should not be viewed as weaker than graded recommendations.

The Work Group took on the primary role of writing the recommendations and rationale statements and retained final responsibility for the content of the guideline statements and the accompanying narrative. The ERT reviewed draft recommendations and grades for consistency with the conclusions of the evidence review.

Format for Guideline Recommendations
------------------------------------

Each chapter contains one or more specific recommendations. Within each recommendation, the strength of recommendation is indicated as level 1 or level 2 and the quality of the supporting evidence is shown as A, B, C or D. The recommendation statements and grades are followed by the rationale and clarification of the wording of the statement, a brief background with relevant definitions of terms, and then a chain of logic which summarizes the key points of the evidence base and the judgments supporting the recommendation. Some sections also contain research recommendations in variable degrees of detail, suggesting future research to resolve current uncertainties.

Limitations of Approach
-----------------------

Although the literature searches were intended to be comprehensive, they were not exhaustive. MEDLINE was the only database searched. Hand searches of journals were not performed, and review articles and textbook chapters were not systematically searched. However, important studies known to domain experts that were missed by the electronic literature searches were added to the retrieved articles and reviewed by the Work Group.

Summary of the Review Process
-----------------------------

Several tools and checklists have been developed to assess the quality of the methodological process for systematic review and guideline development. These include the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria,^[@bib726]^ the Conference on Guideline Standardization (COGS) checklist,^[@bib727]^ and the Institute of Medicine\'s recent *Standards for Systematic Reviews*^[@bib728]^ and *Clinical Practice Guidelines We Can Trust*.^[@bib729]^ [Table 45](#tbl45){ref-type="table"} and Appendix 1 demonstrate the level of concurrence to the COGS criteria and the Institute of Medicine standards, respectively.

**SUPPLEMENTARY MATERIAL**

*Supplemental Table 1:* Search strategy.

*Appendix 1:* Concurrence with Institute of Medicine standards for systematic reviews and for guidelines.

**Supplementary material** is linked to the online version of the paper at <http://www.kdigo.org/clinical_practice_guidelines/ckd.php>
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###### The Conference on Guideline Standardization[@bib727] checklist for reporting clinical practice guidelines
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